Pradžia › Mielofibrozė › Alabama
Mielofibrozė klinikiniai tyrimai Alabama
7 tyrimai dėl Mielofibrozė ieško dalyvių vietose Alabama.
Miestai Alabama
Oficialus tyrimo tekstas (anglų kalba)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Alabama, Birmingham
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04176198Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Alabama At Birmingham, Birmingham
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT07441694UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai1 fazė
4 Weeks – 75 Years · Visoms lytims · Atnaujinta 2026-04-13 · NCT06047886A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UAB Hospital, Birmingham
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- University of Alabama at Birmingham, Birmingham
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2023-02-21 · NCT05280509Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.